Karuna Therapeutics Inc. (KRTX)
NASDAQ: KRTX
· Real-Time Price · USD
329.83
0.09 (0.03%)
At close: Mar 15, 2024, 9:00 PM
Karuna Therapeutics Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
Fiscal Year | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 185.82M | 184.47M | 263.6M | 562.66M | 248.33M | 628.32M | 136.1M | 176.2M | 206.95M | 252.22M | 345.65M | 353.69M |
Short-Term Investments | 1.08B | 1.16B | 1.17B | 909.76M | 875.72M | 563.72M | 271.32M | 266.98M | 287.04M | 246.68M | 197.98M | 217.61M |
Long-Term Investments | n/a | -2.03M | -2.03M | n/a | 261K | 261K | 261K | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 382K | 2.42M | 2.57M | 479K | 690K | 423K | 455K | 764K | 792K | 769K | 990K | 1.27M |
Receivables | 4.9M | 4.9M | n/a | n/a | 57K | 81K | 4.75M | n/a | 1.75M | n/a | n/a | n/a |
Inventory | 32.83M | 7.5M | n/a | n/a | 28.32M | 24.88M | 10.72M | n/a | 20.89M | n/a | n/a | n/a |
Other Current Assets | 14.77M | 11.49M | 6.69M | 35.34M | 2.34M | 2.68M | 1.3M | 1.95M | 708K | 697K | 783K | 535K |
Total Current Assets | 1.32B | 1.37B | 1.45B | 1.51B | 1.15B | 1.22B | 424.18M | 464.64M | 517.33M | 529.44M | 567.1M | 590.02M |
Property-Plant & Equipment | 20.51M | 19.32M | 19.62M | 7.93M | 7.88M | 8.05M | 8.66M | 9.07M | 9.54M | 9.89M | 9.1M | 1.98M |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | -1.46M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 20.9M | 19.7M | 20.16M | 8.41M | 8.56M | 8.73M | 9.38M | 9.84M | 10.34M | 10.66M | 10.09M | 3.25M |
Total Assets | 1.34B | 1.39B | 1.47B | 1.52B | 1.16B | 1.23B | 433.56M | 474.47M | 527.67M | 540.1M | 577.19M | 593.26M |
Account Payables | 6.78M | 2.94M | 1.1M | 476K | 2.38M | 15.72M | 3.92M | 1.48M | 1.94M | 1.99M | 1.97M | 1.3M |
Deferred Revenue | 41.61M | 44.13M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Short-Term Debt | 2.84M | 1.8M | 1.98M | 2.07M | 2.28M | 2.28M | 2.26M | 2.22M | 2.17M | 2.13M | 1.96M | 862K |
Other Current Liabilities | 16.89M | 104K | 35.52M | 22.69M | 29.29M | 22.75M | 17.69M | 12.23M | 16.1M | 11.66M | 6.38M | 4.47M |
Total Current Liabilities | 68.13M | 48.97M | 38.6M | 25.24M | 33.95M | 40.74M | 23.87M | 15.92M | 20.21M | 15.78M | 10.31M | 6.63M |
Long-Term Debt | 13.85M | 13.81M | 13.83M | 2.69M | 3.05M | 3.61M | 4.17M | 4.76M | 5.33M | 5.89M | 6.44M | 1.62M |
Other Long-Term Liabilities | n/a | n/a | 104K | 104K | 104K | 104K | 104K | 104K | 104K | 104K | 104K | 104K |
Total Long-Term Liabilities | 13.85M | 13.81M | 13.94M | 2.8M | 3.15M | 3.71M | 4.28M | 4.86M | 5.43M | 5.99M | 6.54M | 1.72M |
Total Liabilities | 81.97M | 62.78M | 52.54M | 28.03M | 37.1M | 44.46M | 28.15M | 20.79M | 25.64M | 21.77M | 16.85M | 8.35M |
Total Debt | 16.69M | 15.61M | 15.81M | 4.76M | 5.33M | 5.89M | 6.44M | 6.98M | 7.5M | 8.02M | 8.4M | 2.48M |
Common Stock | 4K | 4K | 4K | 4K | 3K | 3K | 3K | 3K | 3K | 3K | 3K | 3K |
Retained Earnings | -997.89M | -884.06M | -764.94M | -661.78M | -564.21M | -488M | -411.03M | -346.09M | -287.87M | -259.91M | -208.98M | -174.56M |
Comprehensive Income | 211K | -2.93M | -3.64M | -1.61M | -3.29M | -3.7M | -3M | -2.54M | -497K | -35K | -5K | 9K |
Shareholders Equity | 1.25B | 1.32B | 1.42B | 1.49B | 1.13B | 1.18B | 405.41M | 453.69M | 502.03M | 518.33M | 560.34M | 584.91M |
Total Investments | 1.08B | 1.16B | 1.17B | 909.76M | 875.72M | 563.72M | 271.32M | 266.98M | 287.04M | 246.68M | 197.98M | 217.61M |